Sign inSubmit
Tips: “quotes” for a phrase · author:Lee · a DOI goes straight to its article

82 results for “Clinical Trial”
Set a search alert
Research ArticleOpen accessPhrase in the titleGeneral Linear Models in a Missing Outcome Environment of Clinical Trials Incorporating with Splines for Time-Invariant Continuous AdjustmentMinjeong Park, Dejian Lai, Xianglin L. Du et al.Missing data is a common occurrence in longitudinal studies of health care research. Although many studies have shown the potential usefulness of current missing analyses, e.g., (1) Complete Case (CC) analysis; (2) imputation methods such as Last Observation Carried Forward (LOCF), multiple imputations, Expectation-Maximization algorithm approach; and (3) methods using all available data such as linear mixed model and generalized … …Current Research in Biostatistics, Vol. 5, Issue 1 · 18 Aug 2015 · 7,401 accessesView PDFCite
Research ArticleOpen accessPhrase in the titleModeling Heterogeneity in Phase II Clinical TrialsChristopher N. Barnes, Shesh N. RaiProblem statement: The common assumption in non-randomized Phase II clinical trials is a homogeneous population with homogeneous response. This assumption is at odds with many trials today; a heterogeneous response due to the existence of subgroups. Approach: In order to examine the effects of heterogeneity on the trial outcome, a systematic platform is developed to quantify the range and classes … …Current Research in Biostatistics, Vol. 1, Issue 1 · 30 Jun 2010 · 10,127 accessesView PDFCite
Research ArticleOpen accessPhrase in the titleQuality of Life in Hematologic Cancer Patients: A Randomized Clinical Trial of Low Dose Naltrexone Versus PlaceboMohammad Ali Seifrabiei, Mohammad Abbasi, Ali Montazeri et al.This study aimed to investigate its effect on hematologic cancer patients. This was a randomized controlled trial assessing quality of life in patients with hematologic malignancies from a single institute in Hamedan. Patients were allocated into two study arms and in addition to their routine treatment received either daily naltrexone 3 mg capsules (treatment group) or 3 mg starch (placebo … …American Journal of Applied Sciences, Vol. 5, Issue 7 · 31 Jul 2008 · 7,399 accessesView PDFCite
Research ArticleOpen accessPhrase in the titleA Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical TrialsMourad Tighiouart, Quanlin Li, Steven Piantadosi, Andre RogatkoWe describe a Bayesian adaptive design for early phase cancer trials of a combination of three agents. This is an extension of an earlier work by the authors by allowing all three agents to vary during the trial and by assigning different drug combinations to cohorts of three patients. The primary objective is to estimate the Maximum Tolerated Dose (MTD) … …Current Research in Biostatistics, Vol. 6, Issue 1 · 25 Aug 2016 · 8,421 accessesView PDFCite
Research ArticleOpen accessPhrase in the titlePlacebo-Driven Clinical Trials of Transfer Point Glucan #300 in Children with Chronic Respiratory Problems: III. Clinical FindingsVetvicka Vaclav, Richter Josef, Svozil Vladimir et al.The role of glucan in stimulation of immune reactions has been studied for decades. In this report we focused on the effects of orally administered glucan in children with chronic respiratory problems. We measured the physical endurance using a 6MWT test and the levels of eNO in 50 children aged 8-12 years and evaluated the effects of 100 mg/d oral … …American Journal of Immunology, Vol. 9, Issue 3 · 20 Aug 2013 · 9,028 accessesView PDFCite
Research ArticleOpen accessPhrase in the titlePlacebo-Driven Clinical Trials of Transfer Point Glucan #300 in Children with Chronic Respiratory Problems: Antibody ProductionVetvicka Vaclav, Richter Josef, Svozil Vladimir et al.The role of glucan in stimulation of immune reactions has been well-established. In this report, we focused on the antibody production in glucan-supplemented children with chronic respiratory problems. We measured the levels of salivary IgA, IgM and IgG in 40 children aged 8-12 years and evaluated the effects of 100 mg d-1 oral dose of glucan. We found a significant … …American Journal of Immunology, Vol. 9, Issue 2 · 5 Jun 2013 · 10,462 accessesView PDFCite
Research ArticleOpen accessEvery word in the titleOral Administration of Gelatin Hydrolysate Reduces Clinical Signs of Canine Osteoarthritis in a Double-Blind, Placebo-Controlled TrialA.C. Beynen, H.W. Van Geene, H.V. Grim et al.Problem statement: There are indications that the intake of gelatin hydrolysate has a beneficial impact on the clinical signs of osteoarthritis in dogs. Data from a controlled trial were required to substantiate these indications. Approach: A double-blind, placebo-controlled trial with privately owned dogs was carried out to assess the efficacy of a preparation of gelatin hydrolysate in the treatment of … …American Journal of Animal and Veterinary Sciences, Vol. 5, Issue 2 · 30 Jun 2010 · 18,245 accessesView PDFCite
Research ArticleOpen accessEvery word in the titleInfluence of Dietary Beta-1,3/1,6-Glucans on Clinical Signs of Canine Osteoarthritis in a Double-Blind, Placebo-Controlled TrialA.C. Beynen, E. LegersteeProblem statement: There are indications for a beneficial effect of beta-1,3/1,6-glucans on the clinical signs of dogs with osteoarthritis. Data from a controlled trial were necessary to prove or disprove the indications. Approach: A double-blind, placebo-controlled trial with privately owned dogs was carried out to assess the efficacy of a preparation of beta-1,3/1,6-glucans in the treatment of osteoarthritis. With the … …American Journal of Animal and Veterinary Sciences, Vol. 5, Issue 2 · 30 Jun 2010 · 10,105 accessesView PDFCite
Research ArticleOpen accessEvery word in the titleRandomized Clinical Stroke Trials in 2009Meheroz H. RabadiProblem statement: Stroke ranks as the leading cause of serious, long-term disability and death world-wide. It is estimated direct and indirect cost of stroke for 2009 was $68.9 billion. Approach: The objective of this review was to examine the effectiveness of emerging pharmacotherapy’s in patients with acute (≤2 weeks), sub-acute (2-12 weeks) and chronic (≥12 weeks) stroke studied in Randomized … …Current Research in Medicine, Vol. 1, Issue 1 · 30 Jun 2010 · 7,243 accessesView PDFCite
Research ArticleOpen accessEvery word in the titleRandomized Clinical Stroke Trials In 2008Meheroz H. RabadiProblem statement: Stroke ranks as the third leading cause of death and the leading cause of serious, long-term disability; estimated direct and indirect cost of stroke for 2009 was $68.9 billion. Approach: The objective of this review was to examine the effectiveness of emerging pharmacotherapies in patients with acute (≤2 weeks), sub-acute (2-12 weeks) and chronic (≥12 weeks) stroke studied … …Current Research in Medicine, Vol. 1, Issue 1 · 30 Jun 2010 · 8,003 accessesView PDFCite